Nils Eckardt, Vice President Medical Affairs, Europe, shares BeiGene’s innovative vision for patients.
A short summary describing an anti-PD-1 antibody which is the backbone of a suite of immunotherapy combinations designed to avoid tumor resistance.
A short summary describing a unique OX40 agonist that does not block native ligand binding.
A short summary describing an antibody targeting TIM-3 which enhances T cell activity and NK-cell tumor cytotoxicity and may help overcome anti-PD-1 resistance in solid tumors.
A short summary describing an anti-TIGIT antibody which can tip the scales from T-cell suppression to T-cell activation in the tumor microenvironment.